Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Original statement

والتكميم تحديداً يترك المريء عرضةً: بعد عقد كامل في تجربة SLEEVEPASS العشوائية، كان التهاب المريء في 31% من مرضى التكميم مقابل 7% فقط للمجازة، ومريء بارت في 4%.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Sleeve gastrectomy leaves the oesophagus exposed to Barrett's oesophagus (archive: Barrett's in 4% at 10 years in SLEEVEPASS).

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com); not necessarily Elawady's own words

Origin

https://eltayebat.com/rule/bariatric-surgery/

Attribution uncertainty

Editorial summary/narrative and study selection written by the archive operators; the archive states that the cited research documents harm independently of Dr. Diaa's words.

Claimed mechanism

Chronic acid exposure causes metaplasia.

Claimed health effect

Barrett's oesophagus (pre-cancerous change).

Population concerned

Sleeve patients

Geographic restriction by Elawady

not applicable (archive text)

Scientific assessment

Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

That sleeve causes Barrett's oesophagus, illustrated with SLEEVEPASS (4%).

2. What is demonstrably correct?

De novo Barrett's is found after sleeve: pooled 5.6% (I-BAR-04); 15-18.8% in small series (A-BAR-08, A-BAR-09).

3. What is wrong or exaggerated?

SLEEVEPASS found Barrett's in 4% after sleeve AND 4% after bypass (P=.29); the authors said incidence was 'markedly lower than in previous trials and similar after both procedures'. The archive narrative and Arabic headline present the 4% as a sleeve-specific penalty.

4. What remains unclear?

Whether sleeve raises Barrett's compared with untreated obesity is not established; cancer risk unknown.

5. Which studies support it?

A-BAR-08, A-BAR-09, I-BAR-04.

6. Which studies contradict it?

A-BAR-07 (no difference vs bypass).

7. What applies to Germany and Europe?

Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.

8. What is known about Egypt?

No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.

9. What practical conclusion is appropriate?

Endoscopic surveillance after sleeve is advised by some authors; the absolute Barrett's risk appears to be in the single-digit percent range in larger data.

Assessment details

Rationale for certainty of evidence

Barrett's after sleeve is documented (pooled de novo 5.6%), but studies are mostly uncontrolled and heterogeneous, and the only RCT shows no difference vs bypass.

Source quality

Archive editorial; numbers from SLEEVEPASS quoted correctly but framed as sleeve-specific.

Regional transferability

European data.

Individual exceptions

Risk higher with persistent GERD symptoms (meta-regression).

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

The archive says sleeve gastrectomy leaves the gullet exposed to Barrett's oesophagus. Barrett's changes are indeed found in some patients years after sleeve (about 6 in 100 in a pooled analysis). But the Finnish randomized trial quoted by the archive found the same rate (4%) after gastric bypass. So the trial does not show that sleeve specifically causes more Barrett's than bypass.

Studies on this claim

Regional context

Germany / EU

Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.

Egypt

No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.

What applies in my country?

General scientific assessment

Potentially true Barrett's is documented after sleeve, but the archive's key trial shows no sleeve-specific excess.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Reflux, Sleeve Dilation, and Barrett's Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up.. Felsenreich DM et al.. Obes Surg 2017 · PMID 28593484 · DOI 10.1007/s11695-017-2748-9
2. Systematic Endoscopy 5 Years After Sleeve Gastrectomy Results in a High Rate of Barrett's Esophagus: Results of a Multicenter Study.. Sebastianelli L et al.. Obes Surg 2019 · PMID 30666544 · DOI 10.1007/s11695-019-03704-y
3. Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041
4. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229